Prevention of childhood rotavirus disease through the use of Rotarix^™ and RotaTeq^™ vaccines

Bibliography

• PARASHAR UD, HUMMELMAN EG, BREESE JS, MILLER MA, GLASS RI: Global illness and deaths caused by rotavirus diseases in children. Emerg. Infect. Dis. (2003) 9:565-572.
   PubMed Web of Science ®Google Scholar
• PARASHAR UD, GIBSON CJ, BREESE JS, BRESEE JS, GLASS RI: Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis. (2006) 12:304-306.
   PubMed Web of Science ®Google Scholar
• BRESEE JS, PARASHAR UD, WIDDOWSON MA, GENTSCH JR, STEELE AD, GLASS RI: Update on rotavirus vacines. Pediatr. Infect. Dis. J. (2005) 24:947-952.
   PubMed Web of Science ®Google Scholar
• GLASS RI, PARASHAR UD, BRESEE JS et al.: Rotavirus vaccines: current prospects and future challenges. Lancet (2006) 368:323-332.
   PubMed Web of Science ®Google Scholar
• LEPAGE P: Rotavirus infection in Europe: time for effective prevention? Pediatr. Infect. Dis. J. (2006) 25:S5-S6.
   PubMed Web of Science ®Google Scholar
• DENNEHY PH: Rotavirus vaccines: an update. Pediatr. Infect. Dis. J. (2006) 25:839-840.
   PubMed Web of Science ®Google Scholar
• SORIANO-GABARRO M, MRUKOWICZ J, VESIKARI T, VERSTRAETEN T: Burden of rotavirus disease in European union countries. Pediatr. Infect. Dis. J. (2006) 25:S7-S11.
   PubMed Web of Science ®Google Scholar
• FRANCO MA, ANGEL J, GREENBERG HB: Immunity and correlates of protection for rotavirus vaccines. Vaccine (2006) 24:2718-2731.
   PubMed Web of Science ®Google Scholar
• PARASHAR UD, BRESEE JS, GENTSCH JR, GLASS RI: Rotavirus. Emerg. Infect. Dis. (1998) 4:561-570.
   PubMed Web of Science ®Google Scholar
• CHEN CM, HUNG T, BRIDGER JC, MCCRAE MA: Chinese adult rotavirus is a group B rotavirus. Lancet (1985) 2>(8464):1123-1124.
   PubMed Web of Science ®Google Scholar
• SCHNAGL RD, BONIFACE K, CARDWELL P et al.: Incidence of group C human rotavirus in central Australia and sequence variation of the VP7 and VP4 genes. J. Clin. Microbiol. (2004) 42:2127-2133.
   PubMed Web of Science ®Google Scholar
• SANEKATA T, AHMED MU, KADER A, TANIGUCHI K, KOBAYASHI N: Human group B rotavirus infections cause severe diarrhea in children and adults in Bangladesh. J. Clin. Microbiol. (2003) 41:2187-2190.
   PubMed Web of Science ®Google Scholar
• BURNS JW, SIADAT PM, KRISHNANEY AA, GREENBERG HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science (1996) 272:104-107.
   PubMed Web of Science ®Google Scholar
• BALL JM, TIAN P, ZENG CQ-Y, MORRIS AP, ESTES MK: Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science (1996) 272:101-104.
   PubMed Web of Science ®Google Scholar
• DESSELBERGER U, WOLLESWINKEL-VAN DEN BOSCH J, MRUKOWICZ J, RODRIGO C, GIAQUINTO C, VESIKARI T: Rotavirus types in Europe and their significance for vaccination. Pediatr. Infect. Dis. J. (2006) 25:S30-S41.
   Web of Science ®Google Scholar
• NAKAGOMI O, NAKAGOMI T, ARISAWA K: A lack of significant association between the electropherotype or G-serotype of the infecting strain and disease severity of rotavirus gastroenteritis. Arch. Virol. (2006) 151:1947-1960.
   PubMed Web of Science ®Google Scholar
• CHIBA S, YOKOYAMA T, NAKATA S et al.: Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet (1986) 8504:417-421.
   Google Scholar
• VAN DAMME P, GIAQUINTO C, HUET F, GOTHEFORS L, MAXWELL M, VAN DER WIELEN M; REVEAL STUDY GROUP: Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004 – 2005: the REVEAL study. J. Infect. Dis. (2007) 195(Suppl. 1):S4-S16.
   PubMed Web of Science ®Google Scholar
• BARNES GL, CALLAGHAN SL, KIRKWOOD CD, BOGDANOVIC-SAKRAN N, JOHNSTON LJ, BISHOP RF: Excretion of serotype G1 rotavirus strains by asymptomatic staff: a possible source of nosocomial infection. J. Pediatr. (2003) 142:722-725.
   PubMed Web of Science ®Google Scholar
• ANDERSON EJ, WEBER SG: Rotavirus infection in adults. Lancet Infect. Dis. (2004) 4:91-99.
   PubMed Web of Science ®Google Scholar
• GLEIZES O, DESSELBERGER U, TATOCHENKO V et al.: Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr. Infect. Dis. J. (2006) 25:S12-S21.
   Web of Science ®Google Scholar
• DENNEHY PH: Transmission of rotavirus and other enteric pathogens in the home. Pediatr. Infect. Dis. J. (2000) 19:S103-S105.
   PubMed Web of Science ®Google Scholar
• RHEINGANS RD, HEYLEN J, GIAQUINTO C: Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Pediatr. Infect. Dis. J. (2006) 25:S48-S55.
   PubMed Web of Science ®Google Scholar
• BISHOP RF, BARNES GL, CIPRIANI E, LUND JS: Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N. Engl. J. Med. (1983) 309:72-76.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ FR, MATSON DO, CALVA JJ et al.: Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. (1996) 335:1022-1028.
   PubMed Web of Science ®Google Scholar
• KING CK, GLASS R, BRESEE JS, DUGGAN C; CENTERS FOR DISEASE CONTROL AND PREVENTION: Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm. Rep. (2003) 52(RR-16):1-16.
   PubMedGoogle Scholar
• CLEMENS J, RAO M, AHMED F et al.: Breastfeeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement? Pediatrics (1993) 92:680-685.
   PubMed Web of Science ®Google Scholar
• LINHARES AC, BRESEE JS: Rotavirus vaccines in Latin America. Pan. Am. J. Public Health (2000) 8:305-331.
   Web of Science ®Google Scholar
• VESIKARI T, GIAQUINTO C, HUPPERTZ HI: Clinical trials of rotavirus vaccines in Europe. Pediatr. Infect. Dis. J. (2006) 25:S42-S47.
   PubMed Web of Science ®Google Scholar
• VESIKARI T, ISOLAURI E, DELEM A, D'HONDT E, ANDRE FE, ZISSIS G: Immunogenicity and safety of live attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet (1983) 2:807-811.
   PubMed Web of Science ®Google Scholar
• DE MOL P, ZISSIS G, BUTZLER JP, MUTWEWINGABO A, ANDRE FE: Failure of live, attenuated oral rotavirus vaccine. Lancet (1986) 8498:108.
   Google Scholar
• MURPHY TV, GARGIULLO PM, MASSOUDI MS et al.: Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. (2001) 344:564-572.
   PubMed Web of Science ®Google Scholar
• HUPPERTZ HI, SORIANO-GABARRO M, GRIMPREL E et al.: Intussusception among young children in Europe. Pediatr. Infect. Dis. J. (2006) 25:S22-S29.
   PubMed Web of Science ®Google Scholar
• SIMONSEN L, VIBOUD C, ELIXHAUSER A, TAYLOR RJ, KAPIKIAN AZ: More on rotashield and intussusception: the role of age at the time of vaccination. J. Infect. Dis. (2005) 192(Suppl. 1):S36-S43.
   PubMed Web of Science ®Google Scholar
• MURPHY BR, MORENS DM, SIMONSONS L et al.: Reappraisal of the association of intussusception with the licensed life rotavirus vaccine challenges initial conclusions. J. Infect. Dis. (2003) 187:1301-1308.
   PubMed Web of Science ®Google Scholar
• RUIZ-PALACIOS GM, PEREZ-SCHAEL IF, VELAZQUEZ R et al.: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. (2006) 354:11-22.
   PubMed Web of Science ®Google Scholar
• VESIKARI T, MATSON O, DENNEHY P et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. (2006) 354:23-33.
   PubMed Web of Science ®Google Scholar
• DE VOS B, VESIKARI T, LINHARES AC et al.: A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. (2004) 23:S179-S182.
   PubMed Web of Science ®Google Scholar
• Rotarix™ European SPC (2007).
   Google Scholar
• VESIKARI T, KARVONEN A, KORHÔNEN T et al.: Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine (2004) 22:2836-2842.
   Google Scholar
• VESIKARI T, KARVONEN A, PUUSTINEN L et al.: Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr. Infect. Dis. J. (2004) 23:937-943.
   PubMed Web of Science ®Google Scholar
• SALINAS B, SCHAEL IP, LINHARES AC et al.: Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr. Infect. Dis. J. (2005) 24:807-816.
   PubMed Web of Science ®Google Scholar
• LINHARES AC, RUIZ-PALACIOS GM, GUERRERO ML et al.: A short report on highlights of worldwide development of RIX4414: a Latin American experience. Vaccine (2006) 24:3784-3745.
   PubMed Web of Science ®Google Scholar
• PHUA KB, QUAK SH, LEE BW et al.: Evaluation of RIX4414, a live attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled Phase II trial involving 2464 Singapore infants. J. Infect. Dis. (2005) 152(Suppl. 1):S6-S16.
   Web of Science ®Google Scholar
• MACIAS M, LOPEZ P, VELAZQUEZ FR et al.: The rotavirus vaccine RIX4414 (Rotarix™) is not associated with intussusception in one year old infants. 45th Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (16 – 19 December 2005):Abstract G-841.
   Google Scholar
• RUIZ-PALACIOS GM, GUERRERO ML, BAUTISTA-MARQUEZ A et al.: Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics (2007) 120:E253-E261.
   PubMed Web of Science ®Google Scholar
• RUUSKA T, VESIKARI T: Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand. J. Infect. Dis. (1990) 22:259-267.
   PubMed Web of Science ®Google Scholar
• DE VOS B, GILLARD P, CHEUVART B, DEBRUS S, HAN AA, BOUCKENOOGHE A: RIX4414 vaccine efficacy against rotavirus gastroenteritis du to G2P4 strain. 46th Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 – 30 September 2006):Abstract G-618.
   Google Scholar
• VESIKARI T, PRYMULA R, SCHUSTER V et al.: Early protection against rotavirus, Rotarix™ (RIX4414) experience in a European setting. 12th ICID Abstracts. Lisbon, Portugal (15 – 18 June 2006). Intern. J. Infect. Dis. (2006) 10(Suppl. 1):Abstract 68.021.
   Google Scholar
• VESIKARI T, KARVONEN A, PRYMULA R et al.: Human rotavirus vaccine Rotarix is highly efficacious in Europe during the first two years of life. 25th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Porto, Portugal (2 – 4 May 2007):Abstract 84.
   Google Scholar
• EMMANUEL S, PHUA KB, GOH P et al.: Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. 23th Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Valencia, Spain (18 – 20 May 2005).
   Google Scholar
• TEJEDOR JC, DIEZ-DELGADO J, ARISTEGUI J et al.: Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitidis serogroup C vaccine (Meningitec™) in healthy infants from Spain. 24th Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Basel, Switzerland (3 – 5 May 2006):Abstract 456.
   Google Scholar
• SCHUSTER V, OTTO W, COHEN R et al.: Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (Prevenar™) in healthy infants from Spain. 24th Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Basel, Switzerland (3 – 5 May 2006):Abstract 461.
   Google Scholar
• GLASS RI, PARASHAR UD: The promise of new rotavirus vaccines. N. Engl. J. Med. (2006) 354:75-77.
   PubMed Web of Science ®Google Scholar
• CLARK HF, OFFIT PA, PLOTKIN SA, HEATON PM: The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr. Infect. Dis. J. (2006) 25:577-583.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ ZM, GOVEIA MG, STEK JE et al.: Concommitant use of an oral pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr. Infect. Dis. J. (2007) 26:221-227.
   PubMed Web of Science ®Google Scholar
• COMMITTEE ON INFECTIOUS DISEASES: Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics (2007) 119:171-181.
   PubMed Web of Science ®Google Scholar
• CIARLET M, SANI-GROSSO R, YUAN G et al.: Safety and imunogenicity of concomittant use of the pentavalent rotavirus vaccine (RotaTeq™) and oral poliovirus vaccine (OPV). 25th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Porto, Portugal (2 – 4 May 2007):Abstract 79.
   Google Scholar
• VESIKARI T, VAN DAMME P, GOTHEFORS L, GOVELA M, DALLAS M, HEATON P: Efficacy of RotaTeq™ to reduce any severity and severe rotavirus disease in Europe. 25th International Congress of Pediatrics. Athens, Greece (25 – 30 August 2007):Abstract PP 1005.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Postmarketing monitoring of intussusception after RotaTeq™ vaccination – United States, 1 February 2006 – 15 February 2007. MMWR Morb. Mortal. Wkly Rep. (2007) 56:218-221.
   PubMedGoogle Scholar
• WHO: Report of the meeting on future directions for rotavirus vaccine research in developing countries. World Health Organization, Geneva, Switzerland (2000):1-56.
   Google Scholar
• GLASS RI, BHAN MK, RAY P et al.: Development of candidate rotavirus vaccines derived from neonatal strains in India. J. Infect. Dis. (2005) 192(Suppl. 1):S30-S35.
   PubMed Web of Science ®Google Scholar
• DAS BK, GENTSCH JR, HOSHINO Y et al.: Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology (1993) 197:99-107.
   PubMed Web of Science ®Google Scholar
• ITURRIZA GOMARA M, KANG G, MAMMEN A et al.: Characterization of G10P[11] rotaviruses causing acute gastroenteritis in neonates and infants in Vellore, India. J. Clin. Microbiol. (2004) 42:2541-2547.
   PubMed Web of Science ®Google Scholar
• BARNES GL, LUND JS, ADAMS L et al.: Early Phase II trial of human rotavirus vaccine candidate (RV3). Vaccine (2002) 20:2950-2956.
   PubMed Web of Science ®Google Scholar
• KAPIKIAN AZ, SIMONSEN L, VESIKARI T et al.: A hexavalent human rotavirus–bovine rotavirus (UK) reasssortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J. Infect. Dis. (2005) 192(Suppl. 1):S22-S29.
   PubMed Web of Science ®Google Scholar
• CLEMENTS-MANN ML, MAKHENE MK, MRUKOWICZ J et al.: Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3, or 4 in adults, children and infants. Vaccine (1999) 17:2715-2725.
   PubMed Web of Science ®Google Scholar
• ROJAS OL, CAICEDO L, GUZMAN C et al.: Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Viral Immunol. (2007) 20:300-311.
   PubMed Web of Science ®Google Scholar
• WHO: Rotavirus vaccines: WHO position paper. Wkly Epidemiol. Rec. (2007) 82:285-296.
   PubMedGoogle Scholar
• PEREZ-SCHAEL I, SALINAS B, TOMAT M et al.: Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J. Infect. Dis. (2007) 196:537-540.
   PubMed Web of Science ®Google Scholar
• GLASS RI, BRESEE JS, FISCHER TK, PARASHAR UD, STEELE AD: Rotavirus vaccines: targeting the developing world. J. Infect. Dis. (2005) 192(Suppl. 1):S160-S166.
   PubMed Web of Science ®Google Scholar
• WHO: Cost effectiveness of rotavirus vaccines and other interventions for diarrhoeal diseases: meeting report 2006. Wkly Epidemiol. Rec. (2006) 81:350-353.
   Google Scholar
• RHEINGANS RD, CONSTENLA D, ANTIL L, INNIS BL, BREUER T: Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev. Panam. Salud Publica (2007) 4:205-216.
   Web of Science ®Google Scholar
• JIT M, EDMUNDS WJ: Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine (2007) 25:3971-3979.
   PubMed Web of Science ®Google Scholar
• WIDDOWSON MA, MELTZER MI, ZHANG X, BRESEE JS, PARASHAR UD, GLASS RI: Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics (2007) 119:684-697.
   PubMed Web of Science ®Google Scholar